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(RU-486) as Treatment for 
Advanced Cancers
Jerome H. Check and Diane L. Check
Abstract
The fetal placental unit has paternal proteins which would normally result in 
immune rejection of fetus. Thus, to allow growth to 266 days, the mother must 
develop immunosuppressive proteins, cytokines, etc. to allow progression to a 
full-term baby. One of these essential immunomodulatory proteins is called the 
progesterone induced blocking factor (PIBF). Probably, the mechanism involved 
allowing the progesterone receptor antagonist mifepristone to cause termination of 
a pregnancy is by blocking the PIBF protein. There is good evidence that cancerous 
tumors borrow some of the same mechanisms as the fetus to escape immune surveil-
lance, including the PIBF protein. Research data suggest that this protein is made 
and excreted by embryonic cells, mesenchymal cells, and trophoblast cells of the 
fetal placental unit to block the killing effect of natural killer cells and T-cells in the 
fetal microenvironment. Cancer cells do the same. Indeed, there is good evidence 
that mifepristone, a drug approved for pregnancy termination, can significantly 
improve length and quality of life in patients with various advanced cancers.
Keywords: progesterone induced blocking factor, metastatic cancer, progesterone 
receptor antagonists, natural killer cells, membrane progesterone receptors
1. Introduction
A certain minimal level of progesterone must be maintained from ovulation 
until delivery to allow the birth of a full-term live baby [1]. Progesterone (P), acting 
in conjunction with the P receptor, causes the production of a large number of 
various molecules needed for the development of an appropriate secretory endo-
metrium to allow attachment of the blastocyst to the endometrium and adequate 
invasion to the proper depth of the fetal placental unit [1].
Some of the molecules induced are also needed to suppress rejection of the fetal 
semi-allograft. One of these immunomodulatory proteins has been termed the 
progesterone induced blocking factor (PIBF) [2]. There is evidence that PIBF is one 
of the most important immunomodulatory factors produced during pregnancy to 
inhibit immune rejection of the fetal semi-allograft [3, 4].
Progesterone-induced blocking factor is an immunomodulatory protein that 
can suppress or block various aspects of the immune system, especially, but not 
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limited to, natural killer (NK) cells [5, 6]. The blocking effect on cellular immunity, 
especially NK cell cytolytic activity, may be related, at least in part, to a shift from 
thymic helper (TH)-1 to TH2 cytokine dominance [7]. One mechanism by which 
PIBF can suppress NK cell cytolytic activity is by inhibiting degranulation of 
perforin granules, one mechanism used by NK cells to kill other cells [8].
The “parent” form has a molecular mass of 90 kDa and is localized in the centro-
some [9]. Various splice variants of this nuclear protein lead to smaller intracyto-
plasmic molecules that have immunosuppressive activity [9]. The actual full-length 
protein contains 757 amino acids, and the 48 kDa N terminal part is biologically 
active [10]. The PIBF gene has been identified on chromosome 13 in the vicinity of 
breast cancer 1 (BRCA1) or BRCA2 or p53 [11, 12].
Progesterone-induced blocking factor rises precipitously in the serum after 
exposure to P (even in males injected with progesterone) and the source seems to 
be circulating gamma/delta T cells [2]. However, it seems that the main source of 
PIBF that allows the early feta-placental to escape immune surveillance are actually 
cells of the fetal placental unit namely embryonic cells, mesenchymal cells, and 
trophoblast cells [1, 9].
In 2001, Check et al. hypothesized that it is likely that cancer cells might “borrow” 
some of the same mechanisms to escape immune surveillance as the fetal-placental 
unit [13]. Based on their previous research with the PIBF protein, they considered 
that, whereas treatment for infertility or recurrent miscarriage should be aimed at 
increasing the production of the PIBF protein, theoretical treatment for cancer could 
be therapy aimed at suppressing the PIBF protein [13].
Support for this concept was provided by Lachman et al., who showed that many 
different types of cancer cells express this PIBF protein [9]. Though one may think 
that highly proliferating cancer cells may be the ones that have the classic nuclear 
progesterone present, the study by Lachman et al., found many of the cancers 
associated with PIBF were not known to be positive for the nuclear P receptor [9].
Based on this hypothesis, it was considered that a P receptor antagonist/
modulator should cause suppression of PIBF production in rapidly growing cancer 
cells which could overcome the theoretical block of immune function of cellular 
immune cells in the tumor microenvironment.
Mifepristone was the first P receptor antagonist developed [14]. It was a derivative 
of the synthetic progestin norethindrone [14]. It was purposely developed to be an 
abortifacient to alter the endometrium and cause decidual necrosis and cause the tro-
phoblast to separate from the decidua [14–16]. Mifepristone sensitizes the pregnant 
uterus and cervix to endogenous and exogenous prostaglandins increasing uterine 
contractility and helps to induce cervical softening [14–16].
Over the years other benefits of mifepristone, related to its anti-progesterone 
effect, have been developed, including treating uterine leiomyomata and endome-
triosis [17]. The anti-abortifacient drug comes in 200 mg tablets. Since mifepristone 
in higher dosages blocks the glucocorticoid receptor, it has been approved as a 
300 mg tablet to treat Cushing’s syndrome [18].
Thus, we set up a study to determine if we could detect PIBF in various leukemia 
cell lines, and, if so, determine if adding mifepristone to the medium could reduce 
PIBF secretion. To do so we collaborated with Dr. Srivastava from the Roswell Park 
Cancer Institute, who for many years studied protein production by leukemia cell 
lines. Twenty-nine cell lines of diverse lineage were all found to express messenger 
(m) RNA for PIBF [19]. In fact, there was more mRNA dedicated to the production 
of the PIBF protein, by far, than any mRNA for any other protein previously studied 
in these leukemia cell lines [19]. Ten cell lines positive for mRNA for PIBF were tested 
for the PIBF protein using a much less sensitive assay for PIBF than is presently 
available. Four tested positive for the PIBF protein. Addition of progesterone to the 
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media of the cell lines up-regulated mRNA for PIBF and also the PIBF protein [19]. In 
contrast, the addition of mifepristone to the media down-regulated both mRNA for 
PIBF and the 35 kDa PIBF intracytoplasmic splice variant protein (similar in size to 
the PIBF splice variant in fetal-placental cells) [19].
Subsequently studies using other cancer cell lines supported the conclusions 
from the leukemia cell line studies. Kyurkchiev et al. found that glioblastoma 
multiforme also express the intracytoplasmic PIBF protein, but in this case the splice 
variant measured 57 kDa [20]. Gonzalez-Arenas et al. found, similar to the afore-
mentioned leukemia cell line studies, adding P to the media up-regulates the 57 kDa 
intracytoplasmic splice variant of PIBF in glioblastoma multiforme cell lines [21]. 
Interestingly, in addition they added PIBF protein to the media and found that PIBF 
increased the number of U87 cancer cells on days 4 and 5 of treatment. This suggests 
that PIBF promotes proliferation of human glioblastoma cancer cells independent of 
an intact immune system, which would require a whole intact animal or human [21].
Mifepristone has been also found to inhibit the growth of cell lines or murine 
tumor transplantation from endometrial cancer, breast cancer, prostate cancer, 
gastric cancer, ovarian cancer, and lung cancer [22–27].
Goyeneche’s group published some interesting findings concerning mifepristone 
and ovarian cancer cell lines. They have found that mifepristone inhibits ovarian 
cancer cell growth in vitro and in vivo [28]. They have published several studies 
showing the benefit of the combination of mifepristone and chemotherapy with 
cisplatin therapy or cisplatin-paclitaxel treatment of ovarian cell lines [29–31].
Based on these cell line studies, more support was provided that cancer cells 
may borrow some of the same escape mechanisms as the fetal-maternal unit to 
escape immune surveillance. Thus, therapy aimed to suppress these immune factors 
could lead to novel effective anticancer therapies [32]. Dr. Szekeres-Bartho, another 
pioneer in determining that the immunomodulatory protein, PIBF, plays a major role 
in allowing the fetus to avoid immune surveillance, in 2010 wrote a treatise entitled 
“PIBF: the double-edged sword. Pregnancy and tumor” [33].
In an opinion entitled “Pregnancy is a model for tumors, not transplantation,” the 
renowned immunologist Kenneth Beaman, and his group, in 2016, stated “Nearly 65 
years have passed since Peter Medawar posed the following question: “How does the 
pregnant mother contrive to nourish within itself for many weeks or months, a fetus 
that is an antigenic foreign body.” Now, understanding of reproductive immunology 
has demonstrated that the HLA antigens in the placenta are non-classical and do not 
induce rejection. In the placenta and in tumors, 50% or more of the cells are cells of 
the immune system and were once thought to be primed and ready for killing tumors 
or “the fetal transplant” but these cells are not potential killers but abet the growth 
of either the tumor or the placenta. By examining the similarities of the placenta’s 
and tumor’s immune cells, novel mechanisms to cause tumors to be eliminated can 
be designed. Thus, 15 years later, the concept we published in 2001 is starting to be 
accepted by top immunologists in the field [34]. Though Beaman et al. do not refer 
at all to the PIBF protein, I recommend an article in gynecologic oncology to those 
readers wanting further knowledge into the immune similarities between pregnancy 
and cancer to open the door for other novel treatments of malignant tumors other 
than blocking the progesterone receptor [35].
2.  Animal studies with mifepristone in cancers that are, and are not, 
known to Be associated with the classic P nuclear receptor
In humans, the progesterone receptor (PR) is expressed in prostate stroma. 
Reduced PR expression in cancer-associated stroma can be conducive to a tumor 
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microenvironment favorable for cancer cell invasion and tumor metastases [36]. 
Thus, if the presence of the PR somehow inhibits tumor invasion and metastases, 
treating with a PR antagonist may worsen the condition.
However, it may be that the loss of the PR receptor merely suggests a higher 
percentage of more aggressive cells, and thus, mifepristone, by suppressing PIBF, 
may inhibit prostate cancer proliferation. Indeed, gavaging mice with spontaneous 
prostate cancer with mifepristone (which on a weight basis was equivalent to 200 mg 
daily in humans) improved longevity of survival and body condition scores com-
pared to placebo gavaged C57BL/6 mice [37].
Controlled studies were also performed in mice where there was no knowledge 
of the presence of the classic nuclear PR. Beneficial effect on longevity and quality 
of life (body conditioning score) were observed in 129 Pd/J mice with a strong 
predisposition for testicular cancer, in aldo-keto reductase/J mice with spontaneous 
lymphocytic leukemia and A/J mice with spontaneous lung cancer [37–39]. As 
an example, in A/J mice with spontaneous lung cancer, 67.4% treated with mife-
pristone survived 1 year vs. 27% of the controls [39]. Even more important, there 
were 66.7% of mice gavaged with the equivalent of 200 mg/day in humans with 
mifepristone who had no sick days (body conditioning score less than 4) vs. zero 
% for controls [39]. These murine carcinoma studies supported the concept that 
the benefit of mifepristone is not merely for cancers positive for the classic nuclear 
PR. If the mechanism of improvement did operate through the PIBF mechanism, 
the presence of the classic nuclear PR is not needed for production of PIBF expres-
sion by the tumor cells.
3. Case reports
Based on cell line studies and controlled animal studies, we wanted to determine 
if the mifepristone could provide increased longevity and/or improved quality of 
life in human patients with advanced cancer. Unfortunately, though physicians 
generally have the right to use drugs off-label, there was a restriction for mifepris-
tone. This was not related to risk of the drug, but related to appeasing antiabortion 
groups who feared that the drug could find easy use to cause abortions. Thus, to use 
mifepristone as an anticancer drug, one needs to obtain from the Food and Drug 
Administration a compassionate use investigational new drug (IND) approval to 
use mifepristone to treat cancer.
3.1 Case 1
The first patient we treated with oral daily mifepristone 200 mg/day was a 
46-year-old woman diagnosed with a rare thymic epithelial cell cancer. Over a 
one-year period following initial surgery and radiotherapy more cancerous lesions 
developed in the lung. There was no standard chemotherapy, but she was approved 
for experimental octreotide. However, the cancer still progressed. After starting 
mifepristone 200 mg/daily, though, her lung and mediastinum lesions did not 
regress, they remained stable. Clinically, she was feeling much better in that she 
had much less shortness of breath, much less cough and, marked improvement in 
fatigue. This clinical improvement persisted for over 2 years. Her oncologist decided 
that since the lesions were stable, this could be the opportunity to attempt a “cure” 
by a second course of radiotherapy to the mediastinum. She developed pulmonary 
fibrosis from this second course of radiotherapy. According to the thymic Cancer 
Carcinoma Society, she had survived the second longest time of any patient with 
this type of cancer [40]. Now, with more clinical experience, she would have 
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been advised against more radiotherapy and just continue the mifepristone. Most 
metastatic cancers will not be “cured.” The end point of treatment with mifepris-
tone should be quality of life and increased longevity. This first case of our series 
of anecdotal cases treated with mifepristone first started treatment in 2004. It is 
important to note that thyroid epithelial cell cancer is not known to be associated 
with the classic nuclear P receptor.
3.2 Case 2
The second case of advanced cancer that we obtained a compassionate use IND 
to treat was a 61-year-old woman with a 6.5 cm invasive moderately differentiated 
adenocarcinoma of the transverse colon with extensive metastasis to the liver, peri-
toneum, ovary and uterus. She had marked ascites. The two largest liver metastases 
measured 3.1 × 1.3 cm and 2.3 × 1.9 cm. She was advised by her oncologist that even 
with chemotherapy she would only have a 15% chance of living 6 months.
After 1 year of mifepristone therapy 200 mg orally per day her carcinoembryonic 
antigen level had dropped all the way down to 1.6 ng/mL. After 18 months, there had 
not been any growth of her metastatic lesions nor did any new ones appear. She had 
no pain, no vomiting, and she stated her energy was great.
A CT-scan at 22 months showed some growth of the lesions. Nevertheless, she 
was pain free with good energy even at 27 months when ascites began to return 
(it had completely disappeared). She was still ambulatory at 30 months when 
she died.
Several years later talking to her sister we found out that at 18 months, to save 
money, she started taking the mifepristone every other day. Thus, this case helps 
to establish that the daily dosage should not be less than 200 mg/day. The case also 
supports the concept that mifepristone can prolong life and provide palliation for 
cancers not known to be associated with the classic P nuclear receptor [41].
3.3 Case 3
Another 43-year-old woman with stage IV metastatic colon cancer, who had 
progressed despite standard chemotherapy, began single agent mifepristone 
therapy. Similar to the aforementioned case, there was a halt to cancer progression, 
her energy markedly improved, and she had great relief of pain. After 18 months 
some of her metastatic lesions began to grow. She assumed that this was the end of 
her remission, so she stopped the mifepristone, and decided to try a new experi-
mental drug. She died 3 months later [40]. Based on subsequent clinical experi-
ence, we would have advised her that even though the lesions are starting to grow 
again, mifepristone will still prolong a high quality of life, and will prevent rapid 
spread, thus advising her not to stop mifepristone.
3.4 Case 4
An 83-year-old man with rapidly growing stage IV colon cancer with metastases 
to his lungs, liver, peritoneum, and lymph nodes showed no improvement to either 
capecitabine or cetuximab. He was so weak that he could not get out of bed. Within 
2 weeks of 200 mg mifepristone tablets daily obtained with compassionate use his 
energy returned, and he was able to resume normal function and go to restaurants 
and other social events and completely take care of himself (ECOG 0 now). His 
appetite also returned, and he was pain free.
After 4 ½ months of therapy none of his previously rapidly growing metastatic 
lesions grew with the exception of 1 lung lesion that grew 0.3 cm. He had no side 
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effects from treatment. Though he had no kidney metastases, he had pre-existing 
marked renal impairment. He became uremic. His wife was deciding on dialysis or 
not when he died of a sudden myocardial infarction [41].
3.5 Case 5
Sometimes, instead of the mifepristone therapy causing stable disease, or 
changing the pattern from rapid progression to slow progression, the lesions 
may show marked regression. This is evidenced by a 45-year-old woman who 
had widely metastatic leiomyosarcoma despite previous treatment with total 
abdominal hysterectomy and bilateral oophorectomy, letrozole (the tumor was 
estrogen receptor positive), and gemcitabine/docetaxel, and resection of lung 
metastases [40].
She was started on mifepristone 200 mg/day orally. This caused an almost total 
remission, with disappearance of almost all lesions, and those remaining had shown 
marked decrease in size. After 6 months, some lesions began to appear, but they 
were still very small. Nevertheless, without experience with the nature of this drug, 
the oncologist opted to stop mifepristone and place her in an experimental trial. She 
died within 1 month from complications of this new drug [40].
3.6 Case 6
Another case of very rapidly growing advanced cancer showing complete remis-
sion following ingestion of 200 mg/day oral mifepristone was an 80-year-old woman 
with a history of chronic lymphocytic leukemia who developed sudden onset respi-
ratory failure with a po2 of 72 mmHg. Chest X-ray revealed many lung lesions with 
a radiographic diagnosis of probable advanced lung cancer with multiple metastatic 
lesions. Her serum sodium was 118 mmol/L. She refused a surgical diagnosis or 
chemotherapy based on the presumptive clinical diagnosis of small cell lung cancer 
with the syndrome of inappropriate anti-diuretic hormone (SIADH) and the bleak 
prognosis, even with chemotherapy [42].
She sought an alternative treatment and agreed to mifepristone therapy 
200 mg orally daily. Within 1 month her po2 returned to 99-100 mmHg without 
supplemental oxygen. Her serum sodium increased to normal at 145 mmol/L. Her 
CT-scans showed complete disappearance of all lung lesions even 5 years after 
initial diagnosis. There did remain, however, a ground glass appearance in the 
lungs. She died 5½ years later at the age of 85.5 from an acute myocardial infarc-
tion, not from lung cancer [42].
Interestingly, though we know that PIBF is secreted by leukemia cell lines and is 
suppressed by mifepristone, this woman’s CLL slowly progressed while her rapidly 
growing presumed small cell lung cancer had a complete remission [19]. This could 
suggest that mifepristone acts better on rapidly growing cells than slowly growing 
cancers. Of course, it is possible that the mifepristone helped keep the CLL slow 
growing, but that could simply be related to the normal situation of slow progres-
sion with CLL even without treatment. It should be noted that lung cancer, whether 
small cell or non-small cell (which is still possibly the type of cancer this woman 
had though small cell was more likely because of the clinical picture) is not known 
to be associated with nuclear P receptors.
Many cancer therapies are ineffective for brain metastases or primary brain 
cancers because they cannot cross the blood-brain barrier. There is anecdotal 
evidence that mifepristone can cross the blood brain barrier and provide palliative 
benefits for primary brain cancer and brain metastases.
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3.7 Case 7
A 43-year-old male with a 3-week history of severe protracted headaches was 
found to have a large glioblastoma multiforme grade IV that originated in the 
temporal lobe but involved also the frontal, parietal and temporal lobes and metas-
tases to the spinal cord. Despite surgery, radio and chemotherapy, the tumor rapidly 
progressed. He was not considered a candidate for any other therapy. At the time of 
starting mifepristone therapy, he was paralyzed from the neck down and his hands 
were fixed in the clenched position. He slept most of the day, and when awake, was 
not able to carry out conversations [43].
Within 2 weeks of treatment with 200 mg oral mifepristone daily, he became 
much more alert and was able to carry out intelligent conversations. He was now 
able to open his clenched fists and move his hands. He continued treatment for 
3 months and remained alert. However, his paralysis slowly progressed to the point 
where he was having trouble breathing and swallowing. The mifepristone was 
stopped, and he died 2 weeks later [43].
3.8 Case 8
Another case demonstrating that mifepristone can cross the blood brain barrier 
to thwart brain metastases from progressing is a case of a 68 year old male with 
stage IV metastatic non-small cell adenocarcinoma lung cancer with brain metas-
tases who was referred by his oncologist for mifepristone therapy [44]. Based on 
the experimental data with efficacy of mifepristone inhibiting growth of cancer 
cell lines, the beneficial effect in controlled various murine carcinomas, and the 
anecdotal benefits in individual causes with various advanced cancers following 
single agent mifepristone therapy the FDA approved our investigator imitated 
study entitled “A phase II study of treatment with oral mifepristone as salvage 
therapy in patients who have failed two or more previous chemotherapy regimens” 
(www.clinicaltrials.gov).
He had no tumor markers that could provide him targeted therapy. His cancer 
progressed despite 3 rounds of multi-agent chemotherapy including carboplatin/
avastin/docetaxel, pemetrexed, and gemcitabine. In October of 2015 he had a sei-
zure and magnetic resonance imaging indicated a 1 cm right frontal lobe metastatic 
lesion. He received palliative stereotactic radiotherapy to the brain lesion which was 
completed in November 2015.
With deteriorating symptoms, for example, dyspnea on exertion and fatigue and 
with no other treatment options available (PD-L1 marker was negative and check-
point inhibitors were not approved for PD-L1 negative patients at this time), he was 
referred for our FDA study.
In all previous cases, the 200 mg mifepristone tablets were obtained from Danco 
Inc. at a cost of about $500 per month. For the FDA approved investigator-initiated 
study, we decided to use mifepristone 300 mg tablets daily because the company 
Corcept, Inc. which manufactures the 300 mg tablet for treatment of Cushing’s 
syndrome (though the dosage is generally much higher than 300 mg to block the 
glucocorticoid receptor) was willing to provide the drug free to approved patients.
His clinical symptoms improved significantly within 1 month of treatment with 
single agent oral mifepristone 300 mg daily. He was ECOG 1 at the start of therapy 
and after 1 month was ECOG zero. He remains ECOG zero after 4.8 years of treat-
ment, and for the majority of visits, he answers his 43 questions on the quality of life 
evaluation as “not at all” (the best answer that could be given). There has been no evi-
dence of growth of his previous brain metastases or any new lesions by MRI testing.
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One additional important piece of information that his case provides. His meta-
static lesions remained stable for 1.5 years. But after 1½ years, some lesions began to 
grow slowly. His oncologist, based on his experience with other anticancer agents, 
thought that once disease progression began, it usually accelerates rapidly. He thus 
suggested to the patient that he stop the mifepristone, and consider nivolumab 
or pembrolizumab, which had at this time been tried on some patients who were 
PD-L1 negative, or consider another biopsy to determine if a new tumor marker 
could be found that would allow targeted therapy. The patient feeling so good on 
mifepristone therapy and feeling so poorly on all of his previous chemotherapy 
regimens, opted to take our advice and continue on the mifepristone therapy. Now 
3.5 years later and still feeling great, he is very satisfied with his decision not to stop 
mifepristone therapy [44].
This case exemplifies the mistakes, from lack of experience, that we alluded 
to in some of the previous case reports, that is, one should not stop the drug if 
there is the start of tumor progression. There is still a good chance the drug will 
provide continued extension of a good quality life. Naturally, if a new therapy is 
likely to be more effective than the mifepristone therapy, then it would make sense 
to try the new agent. But it makes no sense to try a completely new experimental 
drug with unknown side effects, as tried by some of the previous described cases. 
Furthermore, experience suggests that mifepristone inhibits metastases, but 
cessation of therapy results in rapid spread. This progression can be so rapid that 
it could be too late to resume mifepristone therapy if the new anticancer therapy is 
not working.
Therapy with mifepristone could be considered hormonal therapy, but because 
its hypothesized mechanism is that it removed a block (i.e., PIBF), and thus allows 
the cellular immune system (especially NK cells) to attack cancer cells, it could also 
be considered a form of immunotherapy. The question arises as to whether the drug 
would be effective in cancers positive for the programmed cell death protein ligand 
1 (PD-L1) marker where there was initial response to immunotherapy with a check-
point inhibitor but where the tumor was now showing resistance.
3.9 Case 9
We did describe a case of a 66-year-old woman with stage IV non-small cell lung 
cancer, who not only had the PD-L1 marker, but also her cancer was positive for 
the epidermal growth factor receptor (EGFR). When her cancer began progressing 
following chemotherapy with carboplatin, pemetrexed and bevacizumab regimen 
and the carboplatin and docetaxel regimen, she was started on a targeted therapy 
for the EGFR marker, erlotinib [45]. At that time, there was only first-generation 
tyrosine kinase inhibitors.
When her cancer progressed despite erlotinib, she was treated with 11 cycles of 
the check-point inhibitor nivolumab. It was stopped after 11 months because it was 
apparent the drug was no longer inhibiting her cancer progression. She qualified for 
the investigator-initiated study, and thus she was treated with the 300 mg oral daily 
dose of mifepristone [45].
After 18 months of oral 300 mg single agent mifepristone therapy, there had 
been no cancer progression based on lung CT scans performed every 2 months. In 
fact, some lesions were actually smaller. She was considered ECOG 1 at the start of 
mifepristone therapy. At the end of 1 year, she was still ECOG 1 with a good quality 
of life and normal physical activity.
After 1 year, her pre-existing severe chronic obstructive pulmonary disease 
(COPD) worsened and she required supplemental oxygen to keep her po2 above 
80 mmHg. Based on her COPD, but not her cancer which still had not progressed, at 
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18 months from initiation of treatment, she was an ECOG 3. She died 2 months later 
from pneumonia.
Thus, this patient not only showed that mifepristone can prolong life and 
provide a good quality of life not only in a patient whose lung cancer is positive for 
the PD-L1 marker, but a person who also has the EGFR mutation [45].
Anecdotal cases are important, but more influential to other physicians would be 
a larger series. Even better would be a controlled trial with sufficient power, and the 
very best, a study that has all these qualifications, but is also multi-centered. The 
FDA approved the aforementioned investigator-initiated study for 40 patients. It 
is not considered ethical to have patients with such severe disease and subject them 
to placebo controls. Thus, the study was to evaluate in a larger series the efficacy of 
mifepristone therapy for advanced lung cancer and compare outcome to historical 
controls, that is, from quality of life to life expectancy, when dealing with a similar 
group of patients with lung cancer that has stage IV and failed at least two chemo or 
immunotherapy regimens.
We were allowed two principal investigators. However, as an investigator-
initiated study with no funds provided to the principal investigator by a pharma-
cological company or a grant, we could not find a principal investigator who treats 
a larger population of patients with lung cancer. Thus, we became, by default, 
the only principal investigator. Unfortunately, it is not totally clear to us as to the 
reasons, but despite our efforts we have only recruited the two aforementioned 
patients that were treated in this investigator-initiated study. Perhaps some of the 
fault lies in making the criteria for registering too harsh, but most of the problem 
is that we have not been referred very many patients to even screen for the study. 
Even the physician who referred us our first case who still is doing so well after 
almost 5 years of single agent mifepristone therapy, plus years with no side effects, 
has not referred us another patient [44]. We asked him if he had more patients 
and he stated that he could send us 40 patients in 1 year, but patients do not want 
to travel 100 miles every month to receive the medication. This seem unbelievable 
but this was also related to us by an oncologist whose research with us involving 
PIBF helped him get into medical school, where the patients would only have to 
travel only 15 miles. He was supposed to be our first principal investigator, but his 
associates objected. Even our own well renowned cancer facility at our institution 
turned down the opportunity to be a principal investigator and has never referred 
one patient for treating cancer whether they had lung cancer for this investigator-
initiated study, or for compassionate use for other cancers. From what we have 
ascertained, they refer the patients to hospice when they are at the stage eligible for 
our study. Yet they kindly refer to us many patients to consider oocyte freezing or 
embryo banking before potential ovary damaging therapy.
3.10 Cases 10 and 11
Actually, there were two patients with lung cancer that we screened that 
would have qualified for the investigator-initiated study. They both had stage IV 
non-small cell lung cancer positive for the EGFR mutation that were at the end of 
targeted therapy (erlotinib, afatinib, and osimertinib) because the lesions were 
progressing. They both responded very well to single agent mifepristone. Their 
case reports were accepted for presentation at the 2020 American Association for 
Cancer Research (“Improvement in quality and length of life following treatment 
with mifepristone in women with stage IV non-small cell lung cancer positive for 
the EGFR mutation that previously progressed on targeted therapy”). Because 
our study was not recruiting very well, we advised these two patients to try 
compassionate use 200 mg mifepristone, where the drug can be shipped to their 
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homes, rather than travel thousands of miles monthly to receive the medication 
gratis as required by the study design.
3.11 Case 12
There were two other abstracts accepted by the annual 2020 AACR meeting. The 
title of one tells it all – “Treatment with oral mifepristone enables a patient with 
end-stage pancreatic cancer, in hospice, on a morphine drip, to restore a decent 
quality of life.” The only other patient who we treated with mifepristone from pan-
creatic cancer, similar to the aforementioned patient, demonstrated a marked relief 
of her severe pain that had been present despite opiates. However, her husband, 
a physician, was informed by a major oncologic center of a new phase I research 
study. He quickly brought his wife there for treatment and she died 2 days later from 
cardiac complications of the new drug [40].
3.12 Case 13
A third abstract accepted for the 2020 annual AACR meeting is entitled 
“Palliative benefits of oral mifepristone for metastatic osteosarcoma.” This shows 
the wide diversity of different advanced cancers that have responded to extremely 
well tolerated oral mifepristone, frequently providing the patients their best quality 
of life even when their cancers had not been as advanced. The reason is that even in 
less advanced stages, many of these patients suffered from side effects of chemo-
therapy or even immunotherapy.
Pancreatic cancer and fibrous osteosarcoma are not known to be associated 
with the nuclear P receptor. Other patients with some rare advanced cancers have 
demonstrated significant palliative benefit following mifepristone therapy include 
a malignant fibrous histiocytoma in a 23-year-old male and an extremely aggressive 
transitional cell carcinoma of the renal pelvis [40].
4. Clinical studies using mifepristone to treat cancer
4.1 Cancers positive for the classic progesterone nuclear receptor
The presence of the classic nuclear P receptor in breast cancer tumors has been 
known for at least 40 years [26]. The thinking in those days was that the presence of 
the hormone receptor may be needed for the tumor to proliferate. Thus, intervening 
with the hormone receptor interaction may inhibit cancer growth while not creating 
serious adverse effects in the patient as long as the hormone-receptor interaction 
was not essential to life or well-being.
Based on the beneficial effects of blocking the estrogen receptor with selective 
estrogen receptors, that is, tamoxifen, it is not surprising that mifepristone was 
evaluated for treating advanced breast cancer with the thought that the interaction 
of progesterone with the classic nuclear progesterone receptor could somehow 
allow tumors, for example, breast and ovarian cancer to proliferate.
Mifepristone is a type II progesterone receptor antagonist which promotes 
DNA binding and also promotes progesterone receptor phosphorylation [46]. 
Mifepristone was given to advanced stage tamoxifen resistant women (second 
line setting) and the authors reported a complete or partial response in about 10% 
[47]. However, 6 of the 11 showed stable disease [47]. Another small study found 
an objective response rate of 18% [48]. For first line, mifepristone for untreated 
metastatic breast cancer, a 10% objective response rate was observed [49].
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The main method of evaluating efficacy of anticancer treatments 25–40 years 
ago, and even today, is inhibition of disease progression. Thus, the improvement did 
not seem adequate enough compared to other “more encouraging therapies”. Thus, 
interest waned in treating advanced breast cancer with mifepristone. Subsequently, 
more experience with mifepristone therapy for a variety of advanced cancers will 
show that although sometimes the treatment will cause a very good objective remis-
sion, the majority of the time the drug provides significant palliation and extension 
of a higher quality life while it slows disease progression.
For ovarian cancer not only is the classic nuclear progesterone receptor present 
but it also predicts a favorable outcome [50]. For similar reasoning as with breast 
cancer, mifepristone was given about 20 years ago to patients with ovarian cancer 
who had persistent lesions or recurrent lesions despite one round of chemotherapy 
[51]. Mifepristone 200 mg/day was given daily and continued until disease progres-
sion was found. They were treated for a mean of only 2 months. For 34 patients 
there was a response in 26.5% (9% complete and 17.5% partial) [51]. A second study 
of this drug conducted 10 years later showed a partial response in 42% of patients 
[52]. Again, the drug was stopped if there was any evidence of progression. The 
median time of treatment was 2 months [52]. From what we know today, if they 
would have continued the drug, the ovarian cancer may have progressed slowly 
while the patient maintained a high-quality extension of life [53].
5. Discussion
Should biopsy specimens be tested for PIBF to see if a given patient should be 
treated with mifepristone?
We do not think it would be unreasonable to see if a given specimen produces 
PIBF, but can we be sure that the tests are sensitive enough to deprive a patient the 
potential great benefit of treatment with mifepristone?
Can measurement of serum PIBF be helpful in determining if the cancer is 
responding to mifepristone or if mifepristone therapy is no longer working?
There have been developed more sensitive and specific serum PIBF assays 
[2]. However, based on measurement of serum PIBF in patients with gynecologic 
cancers or breast cancers that are P receptor positive, or even associated with breast 
cancer antigen 1 or 2, the serum level of PIBF may not be helpful for these purposes 
[54, 55]. It is the PIBF in the tumor microenvironment that seems to be most 
important, and this, of course, would be difficult to measure.
The 200 mg daily dosage of mifepristone does not appear high enough to block 
the glucocorticoid receptor. So, another important question, is if it is the action of 
mifepristone on blocking the P receptor that leads to its efficacy in treating cancer 
why does it seem to work in cancers that are not associated with the classic nuclear P 
receptor?
The evidence supports the fact that it acts on membrane P receptors. 
Activation of the nuclear P receptor initiates transcription, which is a slower 
process, whereas rapid activation of the membrane P receptor is a more rapid 
signaling action [46].
Do cancers need to secrete P to activate the membrane P receptor?
It is possible that at a certain stage cancer cells can make P or a P-like substance 
sufficient to interact with membrane P receptors. There is evidence that a large 
variety of cancer cells express the human chorionic gonadotropin (hCG)-beta 
subunit gene [56]. Activation of the hCG beta subunit gene to produce hCG could 
lead to local P production by the cancer cells. Alternatively, there may be some 
other mechanism to activate the membrane P receptor to make PIBF. Even with this 
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scenario, mifepristone could still block the effect of this theoretical non-P mem-
brane P receptor agonist.
Does mifepristone only works when the cancer is at the stage of rapid 
metastasis?
It is possible that all cancers have mRNA to produce PIBF, but only at a certain 
level, that is, perhaps stem cell level is the membrane progesterone receptor is 
activated and PIBF is manufactured. Thus, it is possible that activation of tumor 
secretion of PIBF only occurs at the stage when it is ready to rapidly metastasize. 
About 20% of meningiomas are associated with the classic nuclear P receptor. 
However, a large study comparing mifepristone vs. placebo for unresectable tumors 
did not find any therapeutic benefit for mifepristone vs. placebo [57]. This could 
be because meningiomas are slow growing tumors and the PIBF mechanism is only 
seen with rapidly growing tumors. However, it is also possible that some meningio-
mas are considered benign. Thus, maybe it is the ability to make PIBF that is one 
factor allowing the tumor to follow a benign vs. malignant course. One benefit of 
this large study was to demonstrate a very good safely profile for mifepristone with 
few side effects [57].
Since a compassionate use IND is required by the FDA, that organization is 
reluctant to grant an off-label use unless all “standard” treatments have been 
exhausted. Thus, most of the study subjects in our center have been patients with 
very advanced cancers where there are few, if any, reasonable treatment options.
One exception is a man, who at the age of 58 was found to have bilateral renal 
cell carcinoma with metastases to local lymph nodes [42]. Renal cell carcinoma can 
be multifocal, and even when several lesions are present, the tumor is generally 
not extremely aggressive. Today the recommendation is renal sparing surgery and 
to remove the tumors every time one reaches a certain critical size [58–60]. But 
16 years ago, the recommendation was bilateral nephrectomy.
Since there were no chemotherapy or immunotherapy agents16 years ago for 
renal cell carcinoma, and the patient did not want to become a dialysis cripple, 
the FDA approved a compassionate use IND for oral mifepristone following a 
laparoscopic hemi-nephrectomy with retention of a kidney with three lesions left 
untreated.
After 10 years of single agent treatment, there were no new tumors. The three 
lesions previously noted on the left kidney remained stable [42]. After 10 years his 
diabetes caused kidney failure and the start of dialysis. Thus, he had the 1½ kidneys 
removed. After 2 years of hemo-dialysis, he was approved for a kidney transplant. 
He is still doing well 16 years from initial diagnosis [42].
This case showed that mifepristone can also work to inhibit tumor growth even 
when not at the rapidly growing cell stage. Whether this is specific only for renal 
cell carcinoma, or applies to other malignancies, needs to be determined. Thus, 
perhaps one should consider using mifepristone in earlier stage metastatic cancers 
following tumor remission following treatment with chemotherapy or immuno-
therapy to possibly inhibit recurrence or negate the need to treat with another 
chemotherapy or immunotherapy regimen with morbid side effects.
One final thought. Frequently, once a tumor has widely metastasized che-
motherapy or even immunotherapy may frequently extend life somewhat at the 
expense of significant side effects from treatment. Mifepristone therapy is devoid 
of major side effects, and thus may provide possibly a longer higher quality life 
than “approved therapy.” The treatment of patients with cancer has provided huge 
profits both for the pharmaceutical companies and the treating institutions. So 
realistically it is unlikely that mifepristone therapy will become popular in capitalis-
tic societies.
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However, in some countries needed to provide effective, yet inexpensive treat-
ment, one could consider offering patients oral government provided mifepristone 
rather than expensive chemo or immunotherapy agents. The cost of a mifepristone 
pill in China is 50 cents. In fact, since growth of tumors is still consistent with a 
prolonged good quality life, one could save money on expensive diagnostic tests to 
monitor progression. Possibly mifepristone could be considered first line therapy 
for metastatic disease with consideration of other therapeutic modalities only if 
health deteriorates despite mifepristone therapy.
Since the drug is available as a generic already, it is unlikely any pharmaceutical 
company will invest in larger studies to prove its efficacy. Hopefully, the published 
anecdotal cases, and the easing of the requirements for compassionate use, will 
encourage other clinicians treating patients with advanced cancer to try the drug 
and publish their findings. If enough treating physicians request compassionate use 
IND for mifepristone use, perhaps the FDA will eventually drop the requirement 
of compassionate use IND, facilitating the use for treating physicians around the 
world. Many countries, similar to the United States, at this time also restrict the 
use of mifepristone solely for the purpose of therapeutic abortions, and in some 
countries, it is completely illegal, at least at the relatively inexpensive price for the 
200 mg dosage to use this drug. The use of the 300 mg dosage that does not require 
a compassionate use IND is cost prohibitive. Possibly the manufactures may one 
day reduce the price considerably or it will be manufactured by a generic company 
at a much lower price when the patent expires. Perhaps at a lower cost, insurance 
companies will be happy to pay for off-label use of mifepristone realizing how 
much cheaper it is for cancer therapy than conventional chemo or immunotherapy 
regimens.
As previously mentioned, clinical trials with mifepristone for cancers associated 
with the classic nuclear P receptor were “disappointing” and thus clinical trails 
were not pursued. When these studies were initiated 20–30 years ago, the hope 
was that metastatic cancer can be “cured.” It is now realized that the best hope for 
advanced cancer is a truce with extension of a better quality of life. Also, at that 
time the goal of therapy was to induce a tumor response as evidenced by complete 
or partial tumor regression. We think if they had used the endpoints of quality and 
length of life, they would have had the satisfaction of treatment as we have had in 
these anecdotal cases. The majority of cases do not show tumor regression but stable 
disease and improved quality and length of life.
As far as side effects, the drug has been well tolerated. In higher dosages 
mifepristone can, by blocking the glucocorticoid receptor, lead to higher serum 
cortisol levels which acts on the mineralocorticoid receptor leading to hypoka-
lemia. One has to be careful when using other drugs that can interfere with the 
metabolism of mifepristone leading to hypokalemia. We had one unreported 
case of a woman adding mifepristone to her ongoing treatment with alpelisib, 
which in itself can cause hypokalemia. Whereas the combination led to hypoka-
lemia, neither drug by itself caused it. She was taking just the 200 mg dosage of 
mifepristone.
Similarly, case number 9, who was taking the 300 mg dosage, did develop 
hypokalemia when she was switched to another bronchodilator for her COPD, but 
reverted back to normal when it was stopped. She was taking the 300 mg dosage of 
mifepristone [45].
One man with stage IV non-small cell lung cancer became more somnolent 
when adding mifepristone to his fentanyl that he was using for pain. Though we 
advised him to reduce the dosage of fentanyl, he chose to just stop the mifepristone 
and died 2 weeks later. He had only taken the mifepristone for 2 days.
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